Basit öğe kaydını göster

dc.contributor.authorTÜTÜNCÜ, MELİH
dc.contributor.authorYALÇINKAYA, CENGİZ
dc.contributor.authorUYGUNOĞLU, UĞUR
dc.contributor.authorSAİP, SABAHATTİN
dc.contributor.authorSİVA, AKSEL
dc.contributor.authorGulec, Zeynep Ece Kaya
dc.date.accessioned2023-10-10T10:45:03Z
dc.date.available2023-10-10T10:45:03Z
dc.identifier.citationGulec Z. E. K., UYGUNOĞLU U., TÜTÜNCÜ M., SAİP S., SİVA A., YALÇINKAYA C., "Analysis of determinants of treatment change in adult paediatric-onset MS patients", MULTIPLE SCLEROSIS AND RELATED DISORDERS, cilt.69, 2023
dc.identifier.issn2211-0348
dc.identifier.othervv_1032021
dc.identifier.otherav_0b887efd-a129-4f46-bacb-fcb90f00f772
dc.identifier.urihttp://hdl.handle.net/20.500.12627/189488
dc.identifier.urihttps://doi.org/10.1016/j.msard.2022.104463
dc.description.abstractBackground: Paediatric-onset multiple sclerosis (POMS) is increasing worldwide and represents approximately 5% of all MS cases. Although this patient group has similar characteristics to the adult group, it is important for this patient group to receive effective treatment due to the early onset of cognitive involvement, higher lesion burden, and secondary progression at an earlier age than adults. In this study, we aimed to evaluate the factors that cause treatment change in POMS patients. Material and Method: Adult patients with a first MS attack at age 18 years or younger who were followed up with the diagnosis of MS at the Clinical Neuroimmunology and Demyelinating Diseases outpatient clinic of Cerrahpas,a Medical School between 1987 and 2020 were included in our study. Patient files were reviewed retrospectively, and demographic and clinical characteristics, imaging, first attack characteristics, and treatment change were noted. We included 269 patients with a definite diagnosis of MS in the study, and these patients were evaluated in two groups: negative for treatment change and positive for treatment change. Results: Multifocal involvement was detected more frequently in the group with treatment change (p = 0,049). Cerebellar involvement as a first attack symptom was more common in male patients (p = 0,023) The age at first MS attack was found to be younger (p = 0,006), and the disease duration was longer in the positive for treatment change group (p = 0,003). Spinal cord involvement was more common in the positive for treatment change group (p = 0,016). Abnormal VEP findings were observed more frequently in the group without treatment change (p = 0.018). In multivariant analysis, spinal cord involvement, younger age at first attack, and abnormal VEP findings in the group without treatment change were found to be significant. Among the reasons for treatment change, the most common reason was radiological and clinical progression. Conclusion: The higher inflammatory load in POMS patients compared with adults necessitates early initiation of treatment in this group and timely treatment change to prevent disability. Furthermore, this patient group should be followed closely and receive effective treatment.
dc.language.isoeng
dc.subjectNöroloji (klinik)
dc.subjectYaşam Bilimleri
dc.subjectNöroloji
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectKlinik Tıp
dc.subjectKLİNİK NÖROLOJİ
dc.titleAnalysis of determinants of treatment change in adult paediatric-onset MS patients
dc.typeMakale
dc.relation.journalMULTIPLE SCLEROSIS AND RELATED DISORDERS
dc.contributor.departmentİstanbul Üniversitesi-Cerrahpaşa , ,
dc.identifier.volume69
dc.contributor.firstauthorID4307739


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster